• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠心病患者的医学和社会心理因素与低密度脂蛋白胆固醇控制不佳

Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.

作者信息

Munkhaugen John, Sverre Elise, Otterstad Jan E, Peersen Kari, Gjertsen Erik, Perk Joep, Gullestad Lars, Moum Torbjørn, Dammen Toril, Husebye Einar

机构信息

1 Department of Medicine, Drammen Hospital, Norway.

2 Department of Behavioural Sciences in Medicine and Faculty of Medicine, University of Oslo, Norway.

出版信息

Eur J Prev Cardiol. 2017 Jun;24(9):981-989. doi: 10.1177/2047487317693134. Epub 2017 Feb 14.

DOI:10.1177/2047487317693134
PMID:28196429
Abstract

Objective Understanding the determinants of low-density lipoprotein cholesterol (LDL-C) control constitutes the basis of modelling interventions for optimal lipid control and prognosis. We aim to identify medical and psychosocial (study) factors associated with unfavourable LDL-C control in coronary patients. Methods A cross-sectional explorative study used logistic and linear regression analysis to investigate the association between study factors and LDL-C in 1095 patients, hospitalized with myocardial infarction and/or a coronary revascularization procedure. Data were collected from hospital records, a comprehensive self-report questionnaire, clinical examination and blood samples after 2-36 months follow-up. Results Fifty-seven per cent did not reach the LDL-C target of 1.8 mmol/l at follow-up. Low socioeconomic status and psychosocial factors were not associated with failure to reach the LDL-C target. Statin specific side-effects (odds ratio 3.23), low statin adherence (odds ratio 3.07), coronary artery by-pass graft operation as index treatment (odds ratio 1.95), ≥ 1 coronary event prior to the index event (odds ratio 1.81), female gender (odds ratio 1.80), moderate- or low-intensity statin therapy (odds ratio 1.62) and eating fish < 3 times/week (odds ratio 1.56) were statistically significantly associated with failure to reach the LDL-C target, in adjusted analyses. Only side-effects (standardized β 0.180), low statin adherence ( β 0.209) and moderate- or low-intensity statin therapy ( β 0.228) were associated with LDL-C in continuous analyses. Conclusions Statin specific side-effects, low statin adherence and moderate- or low-intensity statin therapy were the major factors associated with unfavourable LDL-C control. Interventions to improve LDL-C should ensure adherence and prescription of sufficiently potent statins, and address side-effects appropriately.

摘要

目的 了解低密度脂蛋白胆固醇(LDL-C)控制的决定因素是为实现最佳血脂控制和预后制定干预模型的基础。我们旨在确定冠心病患者中与LDL-C控制不佳相关的医学和社会心理(研究)因素。方法 一项横断面探索性研究采用逻辑回归和线性回归分析,调查了1095例因心肌梗死和/或冠状动脉血运重建术住院患者的研究因素与LDL-C之间的关联。数据收集自医院记录、一份全面的自我报告问卷、临床检查以及随访2至36个月后的血样。结果 57%的患者在随访时未达到LDL-C目标值1.8 mmol/l。社会经济地位低下和社会心理因素与未达到LDL-C目标无关。在调整分析中,他汀类药物的特定副作用(比值比3.23)、他汀类药物依从性低(比值比3.07)、冠状动脉搭桥手术作为索引治疗(比值比1.95)、索引事件之前发生≥1次冠状动脉事件(比值比1.81)、女性(比值比1.80)、中低强度他汀类药物治疗(比值比1.62)以及每周吃鱼<3次(比值比1.56)与未达到LDL-C目标在统计学上显著相关。在连续分析中,只有副作用(标准化β 0.180)、他汀类药物依从性低(β 0.209)和中低强度他汀类药物治疗(β 0.228)与LDL-C相关。结论 他汀类药物的特定副作用、他汀类药物依从性低和中低强度他汀类药物治疗是与LDL-C控制不佳相关的主要因素。改善LDL-C的干预措施应确保依从性和使用足够强效的他汀类药物,并妥善处理副作用。

相似文献

1
Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.冠心病患者的医学和社会心理因素与低密度脂蛋白胆固醇控制不佳
Eur J Prev Cardiol. 2017 Jun;24(9):981-989. doi: 10.1177/2047487317693134. Epub 2017 Feb 14.
2
The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event.冠心病事件后 C-反应蛋白升高的患病率及其预测因素。
Eur J Prev Cardiol. 2018 Jun;25(9):923-931. doi: 10.1177/2047487318768940. Epub 2018 Apr 11.
3
The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.他汀类药物治疗期间提高高密度脂蛋白胆固醇的有益效果取决于低密度脂蛋白胆固醇所达到的水平:对冠状动脉粥样硬化进展和心血管事件的影响。
Eur J Prev Cardiol. 2016 Mar;23(5):474-85. doi: 10.1177/2047487315572920. Epub 2015 Feb 17.
4
Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.经皮冠状动脉介入治疗及长期他汀类药物治疗的稳定型冠心病患者中,低密度脂蛋白胆固醇和C反应蛋白的比较预后价值
Cardiovasc Revasc Med. 2014 Apr;15(3):131-6. doi: 10.1016/j.carrev.2014.02.003. Epub 2014 Mar 2.
5
Risk Factors Associated with Failure to Achieve the Low Density Lipoprotein Cholesterol Therapeutic Target in Patients with Acute Coronary Syndrome: A Longitudinal, Single Centre Investigation.急性冠状动脉综合征患者低密度脂蛋白胆固醇治疗目标未达标的相关危险因素:一项纵向单中心研究
High Blood Press Cardiovasc Prev. 2019 Feb;26(1):37-43. doi: 10.1007/s40292-019-00298-5. Epub 2019 Jan 25.
6
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.高剂量与低剂量培伐他汀在日本稳定型冠状动脉疾病患者中的应用(REAL-CAD):一项随机优势试验。
Circulation. 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615.
7
Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS).他汀类药物逃逸现象对急性心肌梗死患者长期临床结局的影响:名古屋急性心肌梗死研究(NAMIS)的亚组分析
Atherosclerosis. 2015 Sep;242(1):155-60. doi: 10.1016/j.atherosclerosis.2015.07.012. Epub 2015 Jul 9.
8
Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.接受高强度或中强度他汀类药物治疗的患者的治疗模式和低密度脂蛋白胆固醇(LDL-C)达标情况。
Clin Res Cardiol. 2018 May;107(5):380-388. doi: 10.1007/s00392-017-1193-z. Epub 2017 Dec 22.
9
Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.来自24个欧洲国家的冠心病患者的降脂药物治疗——EUROASPIRE IV调查结果
Atherosclerosis. 2016 Mar;246:243-50. doi: 10.1016/j.atherosclerosis.2016.01.018. Epub 2016 Jan 13.
10
Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade?他汀类药物的依从性和 LDL 胆固醇水平。我们是否应该在升级他汀类药物之前评估其依从性?
Eur J Intern Med. 2015 May;26(4):268-72. doi: 10.1016/j.ejim.2015.02.014. Epub 2015 Mar 11.

引用本文的文献

1
From guidelines to practice: LDL-C achievement in very high cardiovascular risk patients - analysis of the EDHIPO MARCA registry.从指南到实践:极高心血管风险患者的低密度脂蛋白胆固醇达标情况——EDHIPO MARCA注册研究分析
Lipids Health Dis. 2025 Sep 2;24(1):275. doi: 10.1186/s12944-025-02657-9.
2
LDL-C achievement in patients with coronary artery disease: a study protocol for the EDHIPO-MARCA retrospective registry.冠心病患者低密度脂蛋白胆固醇(LDL-C)达标情况:EDHIPO-MARCA回顾性注册研究方案
BMJ Open. 2025 Sep 2;15(9):e100569. doi: 10.1136/bmjopen-2025-100569.
3
Low-Density Lipoprotein Cholesterol Increases Significantly During Brief Discontinuation of Atorvastatin and Correlates With Metabolite Half-Lives.
阿托伐他汀短暂停药期间低密度脂蛋白胆固醇显著升高,并与代谢物半衰期相关。
Pharmacol Res Perspect. 2025 Apr;13(2):e70082. doi: 10.1002/prp2.70082.
4
Atherogenic lipid profile in patients with statin treatment after acute coronary syndrome: a real-world analysis from Chinese cardiovascular association database.他汀类药物治疗急性冠脉综合征后患者的致动脉粥样硬化脂质谱:中国心血管协会数据库的真实世界分析。
Lipids Health Dis. 2024 Aug 28;23(1):271. doi: 10.1186/s12944-024-02244-4.
5
Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs.挪威他汀类药物治疗的缺口与中断:优化降脂药物管理的潜力
Eur Heart J Open. 2022 Oct 27;2(6):oeac070. doi: 10.1093/ehjopen/oeac070. eCollection 2022 Nov.
6
Medication adherence among persons with coronary heart disease and associations with blood pressure and low-density-lipoprotein-cholesterol.冠心病患者的药物依从性及其与血压和低密度脂蛋白胆固醇的关系。
Eur J Clin Pharmacol. 2022 May;78(5):857-867. doi: 10.1007/s00228-022-03276-4. Epub 2022 Jan 21.
7
Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects.冠心病患者他汀类药物相关肌肉副作用的临床和心理因素。
BMC Cardiovasc Disord. 2021 Dec 16;21(1):596. doi: 10.1186/s12872-021-02422-7.
8
Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7.特罗姆瑟 7 号人群中冠心病患者对处方指南的遵守情况和治疗目标的实现情况。
BMC Cardiovasc Disord. 2021 Jan 21;21(1):44. doi: 10.1186/s12872-021-01866-1.
9
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).用于预防动脉粥样硬化性心血管疾病的低密度脂蛋白胆固醇降低策略:聚焦靶向 PCSK9(inclisiran)的 siRNA 治疗。
Curr Cardiol Rep. 2020 Oct 21;22(12):176. doi: 10.1007/s11886-020-01427-6.
10
Trends of Clinical Outcomes and Health Care Resource Use in Heart Failure in the United States.美国心力衰竭临床结局和医疗资源使用趋势。
J Am Heart Assoc. 2020 Jul 21;9(14):e016782. doi: 10.1161/JAHA.120.016782. Epub 2020 Jul 4.